Despite the overall efficacy of antidepressant and antipsychotic combination therapy for the treatment of psychotic depression, data on the most appropriate choice of individual drugs for the combination treatment are limited. Researchers recently conducted a network meta-analysis to compare the efficacy and safety of various pharmacological treatment options for patients who had major depressive episodes with psychotic features (Oliva et al., 2024).
Topiramate (generic) — Topamax (brand)
Differences in study population characteristics and treatment modalities were largely responsible for the discordant findings between the two adequately powered trials that have compared ketamine treatment and electroconvulsive therapy (ECT) for major depressive disorder, an analysis has concluded. Remission rates with ECT treatment diverged significantly, at 63% in one of the studies and 22% in the other. Results of the analysis were published online Dec. 19, 2023 in the International Journal of Neuropsychopharmacology.
A systematic review and meta-analysis based on 22 studies has concluded that antidepressant treatment for late-life depression improves cognitive function, particularly in the domains of memory and learning. Results supported an association between reduced depressive symptoms and improvement in cognition. Results of the review and meta-analysis were published online Feb. 7, 2024, in the American Journal of Psychiatry.
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：